

PRESS RELEASE

Cordlife Opens the Largest Stem Cell Banking Facility in Indonesia

- Cordlife has invested in a new stem cell facility in Indonesia to capture burgeoning demand for stem cell banking locally.
- New Cordlife facility in Central Jakarta is the largest stem cell banking facility in Indonesia, with seven times more stem cell storage capacity than its previous facility.
- The new facility also features dedicated laboratory areas for diagnostic testing as Cordlife seeks to serve growing demand for genetic testing.

Singapore, 17 May 2019 – Singapore Exchange mainboard-listed Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”), announced today the official opening of its new stem cell banking facility in Central Jakarta, Indonesia, to capture burgeoning demand for stem cell banking locally. Their new facility is the largest stem cell banking facility in the country with storage capacity for up to 70,000 stem cell units, seven times more than its previous facility.

Strategically located in Central Jakarta, the main CBD area of Indonesia and home of a myriad of diplomatic, business and financial establishments, the new facility helps to bolster the Group’s access to some of the key hospitals located in the area as well as Indonesians’ nascent interest for more diverse healthcare options.

“The opening of our new facility in Indonesia marks Cordlife’s commitment to serving local families for an extended period of time. The month of May is also very special for us at Cordlife Group because we are celebrating 18 years of operations. As we seek to grow and develop this market, we will continue to focus on our core competencies while providing superior service and exceptional value to our customers. Our new strategic location coupled with growing consumer confidence will not only allow us to tap on greater growth opportunities, but also allow us to strengthen our market leadership in the country,” said Ms Tan Poh Lan, Cordlife’s Group CEO and Executive Director.

Besides having a larger stem cell storage capacity, Cordlife’s new facility also features dedicated laboratory areas to cater for potential launch of new products and services. This should significantly strengthen Cordlife’s future expansion plans in Indonesia, through sufficient capability to accommodate growing demands at least for the next 10 years.

Echoing a similar view, Ms Retno Suprihatin, CEO of PT. Cordlife Persada said, “The Indonesian market represents significant growth opportunities for us. With the rising affluence of Indonesians and increasing health consciousness among millennial couples today, this bodes well for our business in Indonesia as a whole. As we seek to further entrench our market leadership in the Indonesia market, we believe that this new facility will help strengthen our foothold here.”

Plans are underway to get the new Cordlife facility audited by assessors from abroad, which will further elevate the Indonesian cord blood banking industry standards to world-class level.

- End -

About PT. Cordlife Persada

PT. Cordlife Persada (“Cordlife Persada” or the “Company”) is a majority-owned subsidiary of Cordlife Group Limited. Established in Indonesia since 2003, PT. Cordlife is the first company in Indonesia to operate a full-fledged cord blood and cord lining processing and storage facility locally. Today, it has evolved to be the market leader of Indonesia’s cord blood banking industry, according to Deloitte.¹ Their facility located in Central Jakarta is currently the largest stem cell banking facility in Indonesia with storage capacity for up to 70,000 stem cell units. The laboratory was also built in accordance to AABB, one of the most respected accreditation body in the industry. Besides having a larger stem cell storage capacity, Cordlife’s new facility also features dedicated laboratory areas, which can be used by the company to perform clinical genetic testing locally such as non-invasive prenatal testing and preimplantation genetic diagnosis. For more information, visit www.cordlife.co.id.

About Cordlife Group Limited

Incorporated in 2001, Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”) is a consumer healthcare group and one of the key providers of cord blood as well as cord lining banking services in Asia. Cordlife has been listed on the mainboard of Singapore Exchange (SGX: P8A) since March 2012.

Cordlife owns the largest network of cord blood banks in Asia with full stem cell banking facilities in six key markets namely Singapore, Hong Kong, Indonesia, India, Malaysia and the Philippines. In Singapore, the Philippines and Indonesia, Cordlife operates the largest private cord blood banks; and is amongst the top three market leaders in India and Malaysia. In January 2018, Cordlife became the market leader in Hong Kong with the acquisition of the largest private cord blood bank in the country, Healthbaby Biotech (Hong Kong) Co., Limited. Through its majority-owned subsidiary in Malaysia, Stemlife Berhad, Cordlife holds indirect stake in Thailand’s largest private cord blood bank, Thai Stemlife. Cordlife also expanded its presence in Myanmar and Vietnam to provide cord blood and cord lining banking services.

Beyond cord blood and cord lining banking, Cordlife offers a comprehensive suite of diagnostics services for the family including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.

Quality and customer focus are amongst some of the cornerstones of Cordlife. The Group’s facilities in Singapore, Hong Kong, India, the Philippines and Malaysia are accredited by AABB,

¹ Source: Deloitte & Touche Financial Advisory Services Limited report, 10 April 2013



the organisation behind the world's gold standard for cord blood banking. In addition, Cordlife Singapore and Healthbaby are accredited by FACT, another world-class accreditation body for cord blood banks globally. This makes Cordlife Singapore and Healthbaby, two of just four cord blood banks in Asia, and seven in the world, to be accredited by both AABB and FACT concurrently. In the area of clinical diagnostics, Cordlife India, Healthbaby and Hong Kong Screening Centre are accredited by the College of American Pathologists ("CAP"). These quality achievements underpin the Group's commitment to providing reliable healthcare solutions to have a better quality of life through innovation and technological advancement.

For more information, visit <http://cordlife.listedcompany.com>.

ISSUED ON BEHALF OF : Cordlife Group Limited

BY : Financial PR Pte Ltd
4 Robinson Road #04-01
The House of Eden
Singapore 048543

CONTACT : Mr Ngo Yit Sung / Mr Benjamin Tho

OFFICE : (65) 6438 2990

EMAIL : yitsung@financialpr.com.sg / benjamin@financialpr.com.sg